Clinical trials: Organ Transplant
Medication Adherence, Liver Transplantation
A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
In solid organ transplant recipients, poor adherence to immunosuppressant medications carries the risk of graft rejection (needing a new transplant), post-transplant complications, and increased healthcare costs.
- Conditions
- Medication Adherence, Liver Transplantation, Kidney Transplantation
- Trial name
- NCT04587024
- Testing
- mHealth intervention, standard of care
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Gastroparesis, Gastroesophageal Reflux
Domperidone for Gastroparesis in Solid Organ Transplantation
The purpose of this study is to examine the clinical response to domperidone in solid organ transplant recipients with gastroparesis.
- Trial name
- NCT00552422
- Testing
- domperidone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- David J. Lederer, M.D.
Immunosuppression, COVID-19
Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid…
- Trial name
- NCT06027229
- Testing
- NVX-CoV2372
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Wisconsin, Madison
Covid19
COVID-19 3rd Dose Vaccine in Transplant Patients
The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.
- Trial name
- NCT05047640
- Testing
- BNT162b2 vaccine, JNJ-78436735 Vaccine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Giselle Guerra
Organ Donation
A Randomized Trial of the Early Referral and Request Approach (ERRA) Intervention to Increase Consent to Organ Donation
The purpose of this study is to evaluate the efficacy and generalizability of a communication intervention (Communication Effectively about Donation (CEaD)) for Organ Procurement Organization (OPO) staff requesters and to compare…
- Trial name
- NCT02138227
- Testing
- Assisted CEaD Condition, Autonomous CEaD Condition
- Where
- 9 sites in United States
- Volunteers
- 273 people
- Sponsor
- Temple University
Pelvic Organ Prolapse
Xenform Postmarket Surveillance Study
To compare transvaginal repair with a biologic graft to traditional native tissue repair in women surgically treated for anterior and/or apical pelvic organ prolapse.
- Trial name
- Xenform (NCT01945580)
- Testing
- Prolapse Repair
- Where
- 25 sites in United States
- Volunteers
- 374 people
- Sponsor
- Boston Scientific Corporation
Organ Transplant
DCD IIT: Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors
The purpose the research is to evaluate whether patients who receive a Donation after Circulatory Death (DCD) heart for cardiac transplantation using either normothermic regional perfusion (NRP) or direct procurement and…
- Trial name
- NCT05462041
- Testing
- DBD Donor Heart Transplantation, DCD Donor Heart Transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cedars-Sinai Medical Center
Cytomegalovirus (CMV) Infection, Kidney Transplantation
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative…
- Trial name
- NCT03629080
- Testing
- HB-101 vaccine
- Where
- 25 sites in United States, Denmark and 4 more
- Volunteers
- 83 people
- Sponsor
- Hookipa Biotech GmbH
Severe Hepatic Veno-Occlusive Disease
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of…
- Trial name
- NCT00358501
- Testing
- Defibrotide
- Where
- 25 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
End Stage Liver DIsease, Liver Failure
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the safety and effectiveness of the VitaSmart™ Liver Machine Perfusion System by comparing clinical outcomes in patients undergoing liver…
- Trial name
- NCT05045794
- Testing
- VitaSmart™Liver Machine Perfusion System, Static cold storage
- Where
- 15 sites in United States
- Volunteers
- 228 people
- Sponsor
- Bridge to Life Ltd.
Primary Graft Dysfunction
Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction
This is a Phase 2 observational nonrandomized pilot investigation to evaluate the safety and efficacy of Sodium Nitrite administration for the reduction of Primary Graft Dysfunction (PGD) in patients undergoing lung transplant.
- Trial name
- NCT01715883
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gladwin, Mark, MD
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation…
- Conditions
- EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT02900976
- Testing
- Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
- Where
- 38 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Oncology Group
Kidney Transplant, Liver Transplant
A Cohort Study of Operationally Tolerant Allograft Recipients
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ.
- Trial name
- ALLTOL (NCT02743793)
- Testing
- Blood Draw
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Transplant
Donors After Circulatory Death Heart Trial
To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
- Trial name
- NCT03831048
- Testing
- OCS Heart System, Cold Storage
- Where
- 25 sites in United States
- Volunteers
- 180 people
- Sponsor
- TransMedics
Heart Transplant
Donor After Circulatory Death Heart CAP Trial
The Portable Organ Care System (OCS™) Heart for Resuscitating, Preserving and Assessing Hearts Donated after Circulatory Death Continued Access Protocol (OCS DCD Heart CAP)
- Trial name
- NCT04615182
- Testing
- Transplant
- Where
- 25 sites in United States
- Volunteers
- 90 people
- Sponsor
- TransMedics
Pelvic Organ Prolapse
Permanent Versus Absorbable Colpopexy Trial
Primary Aim: The primary aim of this randomized controlled trial (RCT) is to compare vaginal mesh and suture exposure rates in women undergoing robotic total hysterectomy and sacrocolpopexy with a light-weight polypropylene mesh…
- Trial name
- PACT (NCT02277925)
- Testing
- Polytetrafluoroethylene, Polydioxanone
- Where
- 5 sites in United States
- Volunteers
- 204 people
- Sponsor
- University of North Carolina, Chapel Hill
Immunosuppression in Solid Organ Transplant
Belatacept in Liver Transplant Recipients
The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant
- Trial name
- NCT00555321
- Testing
- Tacrolimus, Basiliximab, Belatacept More Intensive (MI)
- Where
- 42 sites in United States, Argentina and 7 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Cytomegalovirus (CMV)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting…
- Trial name
- NCT05137717
- Testing
- Maribavir
- Where
- 20 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Takeda
Transplants
Creating a Patient-centered Report Card for Solid Organ Transplant Candidates
Choosing a transplant center that will accept a particular candidate can be difficult and challenging for patients with end-stage organ failure.
- Trial name
- NCT03610555
- Testing
- Intervention 1 - SRTR (age question 1st), Intervention 2 - SRTR (BMI question 1st), Intervention 3 - TCST (age question 1st)
- Where
- United States
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Ajay Israni, MD